Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
Background: The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA....
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225000474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203020042698752 |
|---|---|
| author | M Sereno A Collazo-Lorduy Y Garitaonaindia D Gómez de Antonio J Baena Espinar C Aguado de la Rosa P Cruz Castellanos S Falagán Martínez LE Chara Valverde R López-Castro A López-Martin J Rubio-Pérez A Gómez Rueda C Traseira Puchol X Mielgo Rubio B Losada Vila J Rogado E Bernal Hertfelder L Gutiérrez Sainz JL Campo-Cañaveral I Romano I. Thuissard G Rubio Romero E Casado Sáenz |
| author_facet | M Sereno A Collazo-Lorduy Y Garitaonaindia D Gómez de Antonio J Baena Espinar C Aguado de la Rosa P Cruz Castellanos S Falagán Martínez LE Chara Valverde R López-Castro A López-Martin J Rubio-Pérez A Gómez Rueda C Traseira Puchol X Mielgo Rubio B Losada Vila J Rogado E Bernal Hertfelder L Gutiérrez Sainz JL Campo-Cañaveral I Romano I. Thuissard G Rubio Romero E Casado Sáenz |
| author_sort | M Sereno |
| collection | DOAJ |
| description | Background: The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA. Methods: From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables. Results: Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, p = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, p = 0.001) and FVC (+3.7 % vs. -0.7 %, p = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO. Conclusions: CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies. |
| format | Article |
| id | doaj-art-f0c2073ab0a24ddfa87db2c03013c1b2 |
| institution | OA Journals |
| issn | 2468-2942 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-f0c2073ab0a24ddfa87db2c03013c1b22025-08-20T02:11:37ZengElsevierCancer Treatment and Research Communications2468-29422025-01-014310091010.1016/j.ctarc.2025.100910Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1M Sereno0A Collazo-Lorduy1Y Garitaonaindia2D Gómez de Antonio3J Baena Espinar4C Aguado de la Rosa5P Cruz Castellanos6S Falagán Martínez7LE Chara Valverde8R López-Castro9A López-Martin10J Rubio-Pérez11A Gómez Rueda12C Traseira Puchol13X Mielgo Rubio14B Losada Vila15J Rogado16E Bernal Hertfelder17L Gutiérrez Sainz18JL Campo-Cañaveral19I Romano20I. Thuissard21G Rubio Romero22E Casado Sáenz23Department of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; FIIB HUIS HHEN, Madrid, Spain; IMDEA Precision Nutrition and Cancer Program, Clinical Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain; Corresponding author at: Europe avenue 32, San Sebastian de los Reyes, 28702, Madrid, Spain.Department of Medical Oncology. Puerta de Hierro University Hospital, Majadahonda, Madrid, SpainDepartment of Medical Oncology. Puerta de Hierro University Hospital, Majadahonda, Madrid, SpainThoracic Surger Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain; UAM, Madrid, SpainDepartment of Medical Oncology. 12 de Octubre university Hospital, Madrid, SpainDepartment of Medical Oncology. San Carlos university Hospital, Madrid, SpainDepartment of Medical Oncology. Ciudad Real University Hospital, Castilla La Mancha, SpainDepartment of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; FIIB HUIS HHEN, Madrid, SpainDepartment of Medical Oncology. Guadalajara University Hospital, Castilla la Mancha, SpainDepartment of Medical Oncology. Clinico University Hospital, Valladolid, Castilla León, SpainDepartment of Medical Oncology. Severo Ochoa University Hospital, Leganés, Madrid, SpainDepartment of Medical Oncology. Fundación Jiménez Diáz, Madrid, SpainDepartment of Medical Oncology. Ramón y Cajal University Hospital, SpainDepartment of Medical Oncology. Hospital de Henares, Coslada, Madrid, SpainDepartment of Medical Oncology. Hospital Universitario-Fundación Alcorcón, Alcorcón, Madrid, SpainDepartment of Medical Oncology. Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, SpainDepartment of Medical Oncology. Hospital Universitario Infanta Leonor, Madrid, SpainDepartment of Medical Oncology. Hospital Infanta Cristina, Parla, Madrid, SpainDepartment of Medical Oncology. Hospital Universitario La Paz, Madrid, SpainThoracic Surger Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain; Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid. Villaviciosa de Odón, Madrid, SpainMedicine degree in European University of Madrid. Villaviciosa de Odón, Madrid, SpainDepartment of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; Department of Medical Oncology. Infanta Sofía University Hospital, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid., Madrid, SpainDepartment of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; Department of Medical Oncology. Infanta Sofía University Hospital, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid., Madrid, SpainDepartment of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; FIIB HUIS HHEN, Madrid, Spain; IMDEA Precision Nutrition and Cancer Program, Clinical Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, SpainBackground: The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA. Methods: From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables. Results: Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, p = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, p = 0.001) and FVC (+3.7 % vs. -0.7 %, p = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO. Conclusions: CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.http://www.sciencedirect.com/science/article/pii/S2468294225000474NeoadjuvantOperabilityDLCOChemo-inmunotherapy |
| spellingShingle | M Sereno A Collazo-Lorduy Y Garitaonaindia D Gómez de Antonio J Baena Espinar C Aguado de la Rosa P Cruz Castellanos S Falagán Martínez LE Chara Valverde R López-Castro A López-Martin J Rubio-Pérez A Gómez Rueda C Traseira Puchol X Mielgo Rubio B Losada Vila J Rogado E Bernal Hertfelder L Gutiérrez Sainz JL Campo-Cañaveral I Romano I. Thuissard G Rubio Romero E Casado Sáenz Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 Cancer Treatment and Research Communications Neoadjuvant Operability DLCO Chemo-inmunotherapy |
| title | Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 |
| title_full | Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 |
| title_fullStr | Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 |
| title_full_unstemmed | Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 |
| title_short | Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 |
| title_sort | analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti pd 1 pd l1 |
| topic | Neoadjuvant Operability DLCO Chemo-inmunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2468294225000474 |
| work_keys_str_mv | AT msereno analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT acollazolorduy analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT ygaritaonaindia analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT dgomezdeantonio analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT jbaenaespinar analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT caguadodelarosa analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT pcruzcastellanos analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT sfalaganmartinez analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT lecharavalverde analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT rlopezcastro analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT alopezmartin analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT jrubioperez analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT agomezrueda analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT ctraseirapuchol analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT xmielgorubio analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT blosadavila analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT jrogado analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT ebernalhertfelder analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT lgutierrezsainz analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT jlcampocanaveral analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT iromano analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT ithuissard analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT grubioromero analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 AT ecasadosaenz analysisofoperabilityparameterchangesinneoadjuvanttreatmentwithchemotherapyandantipd1pdl1 |